Skip to main content

Table 1 Risk of recurrence and death according to socio-demographic and clinical characteristics

From: Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study

  Patients Disease-free survival Overall survival
Events (%) HR (95% CI) Events (%) HR (95% CI)
Gender
  Female 246 112 (45.5) Ref 93 (37.8) Ref
  Male 679 334 (49.2) 1.07 (0.85–1.35) 292 (43.0) 1.15 (0.89–1.48)
Age (years)
   < 60 195 70 (35.9) Ref 52 (26.7) Ref
  60–69 312 137 (43.9) 1.32 (0.98–1.77) 115 (36.9) 1.55 (1.11–2.17)
  70–79 281 143 (50.9) 1.77 (1.31–2.37) 132 (47.0) 2.28 (1.64–3.18)
   ≥ 80 137 96 (70.1) 2.99 (2.14–4.16) 86 (62.8) 3.82 (2.64–5.54)
Smoking habits
  Never 178 81 (45.5) Ref 69 (38.8) Ref
  Ever 655 333 (50.8) 1.33 (1.01–1.44) 279 (42.6) 1.35 (1.00–1.83)
  Missing 92 42 (46.6)   37 (40.2) -
Drinking habits
  Never 453 219 (48.3) Ref 183 (40.4) Ref
  Ever 319 157 (49.2) 1.14 (0.90–1.43) 138 (43.3) 1.24 (0.97–1.59)
  Missing 153 70 (45.8)   64 (41.8) -
Cancer site
  Oral cavity 413 199 (48.2) 1.31 (0.92–1.87) 175 (42.4) 1.69 (1.13–2.54)
  Oropharynx 93 43 (46.2) Ref 32 (34.4) Ref
  Hypopharynx 60 36 (60.0) 1.60 (0.99–2.56) 33 (55.0) 1.84 (1.10–3.10)
  Larynx 359 168 (46.8) 1.26 (0.87–1.81) 145 (40.4) 1.52 (1.00–2.30)
pT
  pT1 93 35 (37.6) Ref 24 (25.8) Ref
  pT2 320 145 (45.3) 1.31 (0.89–1.93) 122 (38.1) 1.71 (1.09–2.71)
  pT3 220 103 (46.8) 1.55 (1.03–2.34) 86 (39.1) 1.90 (1.18–3.08)
  pT4 282 158 (56.0) 1.83 (1.23–2.72) 148 (52.5) 2.52 (1.58–4.02)
  Missing 10 5 (50.0)   5 (50.0) -
pN
  pN0 534 212 (39.7) Ref 138 (32.5) Ref
  pN1 121 68 (56.2) 1.67 (1.23–2.26) 59 (49.6) 1.72 (1.23–2.40)
  pN2-pN3 265 162 (61.1) 1.93 (1.42–2.64) 144 (56.1) 2.12 (1.51–2.97)
  Missing 5 4 (80.0)   3 (60.0) -
Grading
  G1 93 37 (39.8) Ref 32 (34.4) Ref
  G2 469 211 (45.0) 1.30 (0.90–1.77) 180 (38.4) 1.21 (0.81–1.80)
  G3 303 166 (54.8) 1.43 (0.97–2.12) 144 (47.5) 1.32 (0.87–2.01)
  Missing 60 32 (53.3)   29 (48.3)  
Surgical margins
  Negative 610 263 (43.1) Ref 224 (36.7) Ref
  Close/positive 243 140 (57.6) 1.31 (1.05–1.63) 120 (49.4) 1.27 (1.00–1.62)
  Missing 72 43 (59.7)   41 (56.9)  
Extranodal extension
  Absent 765 336 (43.9) Ref 283 (37.0) Ref
  Present 160 110 (68.8) 1.34 (1.00–1.79) 102 (63.8) 1.41 (1.04–1.92)
Adjuvant (chemo) radiotherapy
  No 454 198 (43.6) Ref 164 (36.1) Ref
  Yes 463 241 (52.1) 0.76 (0.58–1.01) 214 (46.2) 0.81 (0.60–1.10)
  Missing 8 7 (87.5)   7 (87.5)  
  1. Hazard ratio (HR) and corresponding 95% confidence intervals (CI) were estimated through Cox proportional hazard model, adjusting for study centre, gender, age, cancer site, pT, pN, surgical margins, extranodal extension, and adjuvant (chemo) radiotherapy